if1

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase. BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB).

Kif15-IN-2 is a kinesin Kif15 inhibitor with potential anticancer activity and can be used in prostate cancer research.

Kif15-IN-1 is a kinesin family 15 (Kif15) inhibitor with antiproliferative activity and potential anticancer activity, which can be used to study gastric cancer.

KIF18A-IN-13 (Compound 16) is an effective oral KIF18A inhibitor with in vivo anticancer properties. It can be utilized for the research of ovarian cancer.

KIF18A-IN-14 (Compound Example 81) is an inhibitor of KIF18A that exists in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit the viability of OVCAR-3 cells with IC50 values of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be utilized in tumor research, including studies on colon cancer, breast cancer, and lung cancer.

KIF18A-IN-15 (Compound Example 36) is a KIF18A inhibitor, available in two forms, EX36-A and its enantiomer EX36-B, both with an IC50 range of 0.01-0.1 μM. These compounds inhibit the viability of OVCAR-3 cells, with IC50 values of 0.01-0.1 μM for EX36-A and 0-0.01 μM for EX36-B. KIF18A-IN-15 is applicable in research on tumors, including colon, breast, and lung cancers.

KIF18A-IN-16 (Compound 15) is a polycyclic KIF18A inhibitor. It is applicable in research related to tumors, including colon cancer, breast cancer, and lung cancer.

KIF18A-IN-11 (Compound 13) is an effective inhibitor of KIF18A, exhibiting IC50 values below 100 nM in OVCAR3 and MDA-MB-157 cells. It is applicable for cancer research.

PIF1-IN-1 (Compound 48) is an inhibitor of the hPIF1 helicase, with an IC50 value of 320 μM.

KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A. This compound demonstrates significant anti-tumor properties.

KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.

KIF18A-IN-4 is a moderately potent, non-competitive KIF18A inhibitor of ATP and microtubule with an IC50 of 6.16 μM. It selectively acts on many mitotic kinesins and kinases, without directly affecting microtubule protein assembly, and shows anti-tumour effects.

KIF18A-IN-3 is an efficient KIF18A inhibitor (IC50 = 61nM) that induces mitotic arrest and increases the number of mitotic cells in tumor tissues. It can be used in tumor research.

KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor that suppresses KIF18A microtubule-dependent ATPase activity with an IC50 of 0.016 μM. It reduces HCC15 tumour volume in mouse models and may be employed in KIF18A-associated cancer research.

KIF18A-IN-7 is an orally active inhibitor targeting KIF18A, demonstrating potent inhibition with an IC50 value of 9.4 nM against the microtubule-dependent ATPase activity of KIF18A.

KIF18A-IN-9 (Compound 1), a potent KIF18A inhibitor, exhibits an IC 50 value of 3.8 nM and demonstrates anticancer activity, achieving IC 50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells.

KIF18A-IN-12 (compound 9), a potent KIF18A inhibitor, exhibits an IC 50 of 45.54 nM and is utilized in cancer research.

KIF18A-IN-10 (Compound 24) is a potent inhibitor of KIF18A with an IC50 value of 3.8 nM. It exhibits anticancer activity with IC50 values below 100 nM in OVCAR3 and MDA-MB-157 cells.

HIF1-IN-3 (Benzenepropanamide, N-[(8-hydroxy-7-quinolinyl)(4-methoxyphenyl)methyl]-) is an effective inhibitor of HIF-1 (EC50 = 0.9 μM) and can be used in anticancer studies.

PX-478 is a HIF-1α inhibitor with selectivity, oral activity, and blood-brain barrier permeability. PX-478 has antitumor activity and also protects pancreatic β-cell function in diabetes mellitus and is used in type 2 diabetes mellitus research.

ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.

1,4-DPCA is an inhibitor of prolyl-hydroxylase with an IC50 of 2.4 µM for collagen hydroxylation in human foreskin fibroblasts and 60 μM for factor inhibiting HIF (FIH).

Verucopeptin is a pyranized cyclic peptide and an inhibitor of hypoxia-inducible factor 1 (HIF-1). It is an antibiotic effective against B16 melanoma, with anticancer activity, lowering the expression of HIF-1 target genes and HIF-1α protein levels. It can be used in cancer research.

Oltipraz (RP 35972) is a synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H: quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. Although the exact mechanism through which the anti-angiogenesis effect remains to be fully elucidated, oltipraz maybe able to modulate the expression of a number of angiogenic factors, thereby blocking the sustained and focal neovascularization in multiple tumor cell types.